Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Current Deferred Revenue (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Current Deferred Revenue for 7 consecutive years, with $3.1 million as the latest value for Q1 2026.

  • For Q1 2026, Current Deferred Revenue changed N/A year-over-year to $3.1 million; the TTM value through Mar 2026 reached $3.1 million, changed N/A, while the annual FY2025 figure was $4.2 million, N/A changed from the prior year.
  • Current Deferred Revenue hit $3.1 million in Q1 2026 for Crescent Biopharma, down from $4.2 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $4.2 million in Q4 2025 and bottomed at $3.1 million in Q1 2026.